# MRNA VACCINE DEVELOPMENT

> **NIH NIH N43** · FLAG BIO, INC. · 2024 · $594,566

## Abstract

The contractor will develop mRNAFlag as a vaccine adjuvant.  mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532.  mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.

## Key facts

- **NIH application ID:** 11203921
- **Project number:** 75N93024C00014-0-9999-1
- **Recipient organization:** FLAG BIO, INC.
- **Principal Investigator:** KATERINA ANDRIANOVA
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $594,566
- **Award type:** —
- **Project period:** 2024-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11203921

## Citation

> US National Institutes of Health, RePORTER application 11203921, MRNA VACCINE DEVELOPMENT (75N93024C00014-0-9999-1). Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/grant/nih/11203921. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*